Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The assessment of SpondyloArthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
CAS
PubMed
Google Scholar
Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346(18):1349–56.
CAS
PubMed
Google Scholar
Haroon N. Ankylosis in ankylosing spondylitis: current concepts. Clin Rheumatol. 2015;34(6):1003–7.
PubMed
Google Scholar
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(1):65–73.
PubMed
Google Scholar
Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999–1002.
PubMed
Google Scholar
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90.
PubMed
Google Scholar
Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep. 2008;10(5):371–8.
PubMed
Google Scholar
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998;41(1):58–67.
CAS
PubMed
Google Scholar
Haroon NN, Paterson JM, Li P, Haroon N. Increasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of AS. BMJ Open. 2014;4(12):e006634.
PubMed
PubMed Central
Google Scholar
Salaffi F, Carotti M, Gasparini S, Intorcia M, Grassi W. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes. 2009;7:25.
PubMed
PubMed Central
Google Scholar
Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis. 2004;63(12):1605–10.
CAS
PubMed
PubMed Central
Google Scholar
Boonen A, Severens JL. Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol. 2002;16(4):691–705.
CAS
PubMed
Google Scholar
Boonen A, der HD v, Landewe R, Guillemin F, Rutten-van MM, Dougados M, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis. 2003;62(8):732–40.
CAS
PubMed
PubMed Central
Google Scholar
Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol. 2006;33(2):289–95.
PubMed
Google Scholar
Moon KH, Kim YT. Medical treatment of ankylosing spondylitis. Hip Pelvis. 2014;26(3):129–35.
PubMed
PubMed Central
Google Scholar
Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, et al. 2014 update of the Canadian rheumatology association/Spondyloarthritis research consortium of Canada treatment recommendations for the management of Spondyloarthritis. Part II: specific management recommendations. J Rheumatol. 2015;42(4):665–81.
PubMed
Google Scholar
Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss clinical quality management cohort. Ann Rheum Dis. 2018;77(1):63–9.
CAS
PubMed
Google Scholar
Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65(10):2645–54.
CAS
PubMed
PubMed Central
Google Scholar
Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:24–31.
CAS
PubMed
Google Scholar
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6.
CAS
PubMed
Google Scholar
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.
PubMed
Google Scholar
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.
PubMed
Google Scholar
Inman RD, Davis JC Jr, Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12.
CAS
PubMed
Google Scholar
Ritchlin C, Maksymowych W. MRI outcomes in AS patients after two years of etanercept therapy. Curr Rheumatol Rep. 2006;8(4):253–4.
PubMed
Google Scholar
Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012;71(6):878–84.
CAS
PubMed
Google Scholar
Rahman P, Choquette D, Bensen WG, Khraishi M, Chow A, Zummer M, et al. Biologic treatment registry across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open. 2016;6(4):e009661.
PubMed
PubMed Central
Google Scholar
Thorne C, Bensen WG, Choquette D, Chow A, Khraishi M, Atkins CJ, et al. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry. Arthritis Care Res. 2014;66(8):1142–51.
CAS
Google Scholar
Silverman ED. Canadian rheumatology association meeting Fairmont the Queen Elizabeth Montreal, Quebec, Canada February - March 2, 2019. J Rheumatol. 2019.
Abstracts, 21st PANLAR Meeting. J Clin Rheumatol. 2019;25:S1–S96.
Annual European Congress of Rheumatology EULAR 2019. Ann Rheum Dis. 2019;78(Supplement 2):1–2270.
Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol. 2013;25(3):287–96.
CAS
PubMed
Google Scholar
Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51(Suppl 6):vi37–43.
PubMed
Google Scholar
Glintborg B, Lindstrom U, Aaltonen K, Kristianslund EK, Gudbjornsson B, Chatzidionysiou K, et al. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries. Scand J Rheumatol. 2018;47(6):465–74.
CAS
PubMed
Google Scholar
Kruger K, Burmester GR, Wassenberg S, Bohl-Buhler M, Thomas MH. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int. 2019;39(1):131–40.
PubMed
Google Scholar
Kruger K, Burmester GR, Wassenberg S, Thomas MH. Golimumab as the first-, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or Ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther. 2020.
Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol. 2009;27(6):958–63.
CAS
PubMed
Google Scholar
Manara M, Caporali R, Favalli EG, Grosso V, Atzeni F, Sarzi Puttini P, et al. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017;35(5):804–9.
PubMed
Google Scholar
Kim TJ, Shin JH, Kim S, Sung IH, Lee S, Song Y, et al. Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: observation study of Korean Spondyloarthropathy registry (OSKAR) data. Joint, Bone, Spine. 2016;83(5):569–72.
CAS
PubMed
Google Scholar
Mease PJ, van der Heijde D, Karki C, Liu M, Park Y, Greenberg JD. Tumor necrosis factor inhibitor discontinuation in patients with Ankylosing spondylitis: an observational study from the US-based Corrona registry. Rheumatol Ther. 2018;5(2):537–50.
PubMed
PubMed Central
Google Scholar
Fafa BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, et al. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. Clin Rheumatol. 2015;34(5):921–7.
PubMed
Google Scholar
Molto A, Granger B, Wendling D, Breban M, Dougados M, Gossec L. Brief report: nonsteroidal Antiinflammatory drug-sparing effect of tumor necrosis factor inhibitors in early axial Spondyloarthritis: results from the DESIR cohort. Arthritis Rheumatol. 2015;67(9):2363–8.
CAS
PubMed
Google Scholar
Sorensen J, Hetland ML, all departments of rheumatology in D. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74(3):e12.
PubMed
Google Scholar
Kruger K, Burmester GR, Wassenberg S, Bohl-Buhler M, Thomas MH. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open. 2018;8(6):e021082.
PubMed
PubMed Central
Google Scholar
Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol. 2015;42(7):1105–11.
CAS
PubMed
Google Scholar
Xu Z, Xu P, Fan W, Yang G, Wang J, Cheng Q, et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med. 2017;14(4):3491–500.
CAS
PubMed
PubMed Central
Google Scholar
Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447–51.
CAS
PubMed
Google Scholar